Emerging bispecific antibodies in cancer immunotherapy
As part of an effort to increase antibody efficacy, bispecific antibodies (bsAbs), which can bind two different antigens or epitopes are becoming an area of focus. Most bsABs in trial are cancer therapeutics and this article delves into their potential usage in cancer immunotherapy.
Sheridanc Bispecific Genentech Faricimab Vabysmo Roche Emicizumab Hemlibra Janssen Amivantamab Rybrevant Alex Smith Ozoralizumab Nanozora
Source: news-medical.net